Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Vensica Medical raises $11M to advance Phase 2 trials for its overactive bladder treatment

Vensica Medical a pioneering urology therapeutics company, announced the successful closing of an $11 million funding round. The investment will fund the company's upcoming Phase 2 clinical trials across the United States and Europe for its...

GC Biopharma and Novelty Nobility sign an R&D agreement to develop therapies for geographic atrophy

form of dry AMD that causes damage to retinal tissue, eventually leading to blindness. In the US alone, approximately 1.5 million people are affected by this condition. Last year, the first treatment for GA was approved by the FDA in the US....

BioCryst shares real-world data highlighting strong adherence and persistence with ORLADEYO® (berotralstat)

significant and sustained HAE attack rate reductions after initiating ORLADEYO in patients with HAE, regardless of their C1-inhibitor (C1-INH) deficiency status, and new findings from an HAE patient survey confirming patient preference for an oral...

Great Bay Bio launches its Intelligent Drug Development Ecosystem

On October 18th, the new product launch event hosted by Great Bay Bio (hereinafter referred to as "GBB") was successfully held in Suzhou, where industry players gathered to celebrate the feast of technological innovation. At the event, GBB...

ARTHEx Biotech doses first patient in Phase I-IIa ArthemiR™ trial for Myotonic Dystrophy Type 1

the first participant has been dosed in the Randomized Placebo Controlled Double Blind Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy. Type 1 (DM1). DM1 is a devastating rare neuromuscular disorder that causes muscle weakness and...

The U.S. FDA provides positive guidance on the Phase III trial of 64Cu-SAR-bisPSMA for recurrent prostate cancer.

PET/computed tomography (CT) to detect recurrence of prostate cancer. Evaluation will be across 2 imaging timepoints, Day 1 (day of administration, same-day imaging) and Day 2 (approximately 24 hours post administration, next-day imaging). The...

Aileron Therapeutics will present Phase 1b trial data on low-dose LTI-03 for IPF at the 22nd International Colloquium on Lung and Airway Fibrosis

pulmonary and fibrosis indications, announced the presentation of two abstracts detailing LTI-03's pre-clinical and Phase 1b (NCT05954988) results in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway...

Eisai strengthens its presence in Saudi Arabia by establishing a new pharmaceutical sales subsidiary to enhance its operations in the region

Arabia. Eisai Saudi Arabia is a wholly-owned subsidiary of Eisai’s European regional headquarters, Eisai Europe. In the 1960s, Eisai started business in the Middle East marketing and selling Eisai products through local distribution partners. In...

Blue Earth Therapeutics shares positive Phase 1 results for Lutetium (177Lu) rhPSMA-10.1 Injection, advancing its clinical development

further positive developments for its novel investigational radioligand therapies. Enrolment of patients in the Phase 1 trial of Lutetium (177Lu) rhPSMA-10.1 Injection was completed in July. Early data from the trial suggests an encouraging safety...

Prendio-BioProcure presents PrendioPay, simplifying procurement for life science companie

Prendio-BioProcure, a leader in procurement solutions for the life science industry, is excited to launch PrendioPay, an integrated payment platform that evolves the operational reality that most biotech companies face in their business today –...

HNSA-5487 reduced IgG by over 95% in a first-in-human trial, showing redosing potential

Hansa Biopharma AB, announced positive results from a 12-month follow up analysis from the NICE-01 trial of HNSA-5487, the Company's next generation immunoglobulin G (IgG)-cleaving molecule, assessing IgG recovery, immunogenicity and redosing...

Bruker has acquired Dynamic Biosensors, a pioneer in single-cell interaction cytometry systems, aimed at enhancing drug discovery efforts

Bruker Corporation announced the acquisition of Dynamic Biosensors GmbH, a pioneering company known for its breakthroughs in biosensor development, which is based in Munich, Germany. This acquisition strengthens Bruker’s biophysical portfolio for...

Promega introduces the GloMax® Galaxy Bioluminescence Imager to illuminate protein dynamics in real time

enabling researchers to make meaningful advances in their fields. Promega invites attendees of SFN 2024 to Booth #1316 to experience live demonstrations of the Glomax® Galaxy, showcasing its potential to transform research. About Promega...

BioCare collaborates with AeroSafe Global to introduce sustainable cold chain solutions

in Tempe, Arizona, BioCare, Inc. has been devoted to delivering specialty and therapeutic biological products since 1982. For more information, visit www.BioCare

LenioBio partners with ReciBioPharm to scale up ALiCE® technology and accelerate vaccine production

to accelerate production of vaccine-relevant proteins for use in clinical trials. This project fully aligns with the 100 Days Mission spearheaded by CEPI. The project extension follows a successful first six months during which LenioBio achieved...

ISCT becomes the first cell and gene therapy organization to achieve ANAB accreditation for its workforce development program

international standards of excellence in training and was awarded following a comprehensive audit under the ANSI/ASTM E2659-18 standard. This validates that ISCT's training programs are built on robust quality management systems, thorough learner...

Repare Therapeutics announces promising Phase 1 data showing the effectiveness of Camonsertib in combination with radiotherapy treatment

Treatment of Metastatic Tumors Harboring an Ataxia-Telangiectasia Mutated (ATM) Mutation.” “These encouraging early Phase 1 data build further support for the broad clinical potential of camonsertib,” said Maria Koehler, MD, PhD, Executive Vice...

Doer Biologics announces the dosing of the first patient in a Phase 2 study of DR10624 for severe hypertriglyceridemia treatment.

stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting Fibroblast growth factor 21 receptor (FGF21R), Glucagon-like...

FDA approves Bristol Myers Squibb's COBENFY™, a novel treatment for adult schizophrenia.

medicine in several decades and introduces a fundamentally new approach to treating schizophrenia by selectively targeting M1 and M4 receptors in the brain without blocking D2 receptors “Today’s landmark approval of our first-in-class treatment for...

Galmed releases Phase 3 Aramchol results in Hepatology.

diseases announced that the one-year results of the Open-Label part (ARCON ) of its global Phase 3 trial of Aramchol in 150 patients with NASH and fibrosis (ARMOR) have been published in Hepatology. Previously, Galmed reported results from the...